Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
Xenon XE 133 is an inhaled radioactive gas used as a diagnostic imaging agent for pulmonary ventilation assessment. It enables physicians to visualize lung function and detect abnormalities in air distribution without requiring patient cooperation. The drug works by distributing through the airways and being detected by gamma imaging to map ventilation patterns.
This legacy diagnostic product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling a transition team focused on cost management and efficiency rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With 1,106 linked job opportunities, Xenon XE 133 represents a substantial but operationally-focused career portfolio heavily weighted toward engineering, systems management, and customer support roles rather than traditional pharma commercial functions. Career progression here emphasizes technical infrastructure, supply chain reliability, and customer solutions—ideal for professionals seeking non-commercial pharmaceutical roles.
Worked on XENON XE 133 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
1106 open roles linked to this drug